Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 5, Issue 3, 2003, Pages 163-170

  Jones, T A ^a   Sautter, M ^b   Van Gaal, L F ^c   Jones, Nigel P ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Beta cell function; Glycaemic control; Insulin resistance; Metformin; Obesity; Rosiglitazone; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BODY MASS; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; INJURY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PATIENT CODING; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; STATISTICAL ANALYSIS; UPPER RESPIRATORY TRACT INFECTION; WORLD HEALTH ORGANIZATION;

EID: 0344061039     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2003.00258.x     Document Type: Article

References (23)

1. DeFronzo R. Lilly Lecture 1987: the triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
2. UK Prospective Diabetes Study (UKPDS) group. Intensive blood-glucose control with SUs or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. Serrano-Rios M. Relationship between obesity and the increased risk of major complication in non-insulin dependent diabetes mellitus. Eur J Clin Invest 1998; 28: 14-17.
4. Howard BV. Insulin resistance and lipid metabolism. Am J Cardiol 1999; 84: 28J-32J.
5. UK Prospective Diabetes Study (UKPDS) group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes UKPDS34. Lancet 1998; 352: 854-865.
6. Scheen AJ, Lefebvre PJ. Oral antidiabetic agents. A guide to selection. Drugs 1998; 55: 225-236.
7. Bailey CJ, Turner, RC. Metformin. N Engl J Med 1996; 334: 574-579.
8. Williams G. Management of non-insulin-dependent diabetes mellitus. Lancet 1994; 343: 95-100.
9. Coniff RF, Shapiro JA, Seaton TB et al. Multicenter, placebo controlled trial comparing acarbose (BAYg5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995; 98: 443-451.
10. Whitcomb RW, Saltiel AR. Thiazolidinediones. Expert Opin Invest Drugs 1995; 4: 1299-1309.
11. Lehman JM, Moore LB, Smith-Oliver TA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma. J Biol Chem 1995; 370: 12953-12956.
12. Saltiel AR, Olefsky JM. Thiazolidnediones in the treatment of insulin resistance and Type II diabetes. Diabetes 1996; 45: 1661-1669.
13. Smith SA, Cawthorne MA, Coyle PJ et al. BRL 49653C normalises glycaemic control in zucker fatty fa/fa rats by improving hepatic and peripheral tissue sensitivity to insulin. Diabetologia 1993; 36: A184.
14. Matthews DR, Bakst A, Weston WM et al. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes. Diabetologia 1999; 42: A228.
15. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989; 321: 1231-1245.
16. Fonseca V, Rosenstock J, Patwardhan R et al. Effect of metformin and rosiglitazone combination therapy in patients with Type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283:1695-1702.
17. Lebovitz H, Salzman A. Rosiglitazone safety update. Diabetes 1999; 49: A39.
18. WHO. Prevention and management of the global epidemic of obesity. Report of the WHO consultation on obesity. Geneva: WHO, 1997.
19. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
20. Carey DG, Cowin GJ, Galloway G et al. Effect of rosiglitazone on insulin sensitivity and fat distribution in Type 2 diabetic patients. Obesity Res 2002; 10: 1018-1015.
21. Katoh S, Mori Y, Yokoyama J et al. Effect of oral hypoglycaemic agents on fat distribution and glucose tolerance in non-insulin-dependent diabetes mellitus patients. J Jpn Diabetes Soc 1998; 41: 289-293.
22. Pontiroli AE, Calderara A, Pozza G. Secondary failure of oral hypoglycaemia agents: frequency, possible causes and management. Diabetes Metab Rev 1994; 10: 31-43.
23. Balkau B, Eschwege E. Insulin resistance. an independent risk factor for cardiovascular disease? Diabetes Obes Metab 1999; 1: S23-S31.